A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Top Cited Papers
Open Access
- 8 January 2004
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (2), 125-133
- https://doi.org/10.1056/nejmoa030511
Abstract
Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.Keywords
This publication has 30 references indexed in Scilit:
- Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival∗∗Access the “Journal Club” discussion of this paper at http://www.elsevier.com/locate/ajmselect/American Journal Of Medicine, 2001
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 1999
- Distinct functions of interferon‐γ for chemokine expression in models of acute lung inflammationImmunology, 1998
- DETERMINATION OF VARIOUS CYTOKINES AND TYPE III PROCOLLAGEN AMINOPEPTIDE LEVELS IN BRONCHOALVEOLARAVAGE FLUID OF THE PATIENTS WITH PULMONARY FIBROSIS: INVERSE CORRELATION BETWEEN TYPE III PROCOLLAGEN AMINOPEPTIDE AND INTERFERON-γ IN PROGRESSIVE PATIENTSRheumatology, 1995
- Treatment of systemic sclerosis with γ-interferonBritish Journal of Dermatology, 1992
- In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseasesClinical and Experimental Immunology, 1992
- High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: A randomized, controlled trialHepatology, 1991
- Effects of interferon-gamma on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts.JCI Insight, 1989
- Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.Thorax, 1989
- Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.The Journal of Experimental Medicine, 1983